1Harrogate 2017

CONTENTS2017 Summer Meeting App 2Maps 3–4BAP Officers and Council Members 5General Information 6–72017 BAP Lifetime Achievement Award 8–92017 Prizes Winners 10–11Acknowledgements 12Programme in Detail: Sunday 23 July 13–15 Monday 24 July 16–20 Tuesday 25 July 21–29 Wednesday 26 July 30–312018 Summer Meeting 32Poster Groups 33–47BAP Membership 48

BAP OFFICE36 Cambridge Place, Hills Rd, Cambridge, CB2 1NSwww.bap.org.uk

Executive Officer and Company SecretarySusan Chandler susan@bap.org.uk

Assistant to the Executive OfficerLynne Harmer lynne@bap.org.uk

Online Resources and Communications DeveloperSarah Channing-Wright sarah@bap.org.uk

The scientific material presented at this meeting reflects the opinions of the contributing authors and speakers. The British Association for Psychopharmacology accepts no responsibility for the contents of the verbal or any published proceedings of this meeting.For reasons beyond our control we have the right to immediately alter or cancel the conference or any arrangements, timetable, plans or items relating directly or indirectly to the conference. The participants shall not be entitled to any compensation for damages that result from such alteration or cancellation. It is highly recommended that participants carry the proper individual travel and health insurance.

The British Association for Psychopharmacology is registered in England as a Private Limited Company No. 5866899. Registered Charity No. 277825. Registered Office: 36 Cambridge Place, Hills Road, Cambridge CB2 1NS

2 Harrogate 2017

BAP SUMMER MEETING APPThis year we will have an app that you can download in order to streamline your experience of the Summer Meeting.The app contains networking, interactive calendar, schedules and more.

What you get:• Full programme and personal agenda• Speaker biographies• Meeting related documents• List of exhibitors• Notes facility• Links to social media• Share contact information and network with

other delegates• Venue information and floorplan• Send feedback about the meeting• Certificate of attendance• Updates through push notifications

The app can be downloaded on Android or Apple devices through your app store, just search for BAP Summer Meeting and download onto your device.Open the app and enter the email address you used when you registered for the Summer Meeting, and click ‘Login’.

Only registered delegates can use the app. If you have trouble, please contact Sarah Channing-Wright by email sarah@bap.org.uk, or directly at the BAP Education stand.

BLOGGING AND TWEETING

If you are tweeting during the conference please use hashtag #BAP2017 to share your thoughts and feedback about sessions. Follow us on Twitter @BAPsych.If you would like to contribute to our blog with reviews and reports of meeting sessions you’ve attended during the meeting, please contact Sarah Channing-Wright, sarah@bap.org.uk.

3Harrogate 2017

MAP OF MEETING LOCATIONS

Harrogate

Harrogate Convention Centre

4 Harrogate 2017

POSTERS / EXHIBITION / REFRESHMENTS / LUNCHES

LIFT 1 LIFT 2

Anxiety

Developmental Disorders

Affective Disorders

Cognition

Schizophrenia/Psychosis

Recreational Drugs and Drug Dependence

Poster Groups

ABCDEF

Exhibitors

1 Magna Laboratories

2 Galen-Pharma

3 BAP Education

4 Wisepress

5 LivaNova

6 Tracksys

7 British Pharmacological Society

8 BAP Statistics Clinic

Catering point

Poster touchscreens

Studio 1 Plan

BAP Posters

1

1 2 3

4

567

A

B

C

C

D

E

E

F

F

8

SPEAKERPREVIEW

To Queen’s Suite, King’s Suite and Hall D

Studio 1

5Harrogate 2017

BAP OFFICERS AND COUNCIL MEMBERS

Until the 2017 Annual General Meeting (24 July, Hall D at 17:30)

OfficersPresident: Jo Neill (Manchester)President-elect: Allan Young (London)Past-President: Paul Harrison (Oxford) Honorary Treasurer: Liz Tunbridge (Oxford)Honorary General Secretary: Maxine Patel (London)Meetings Secretary: Mitul Mehta (London)Secretary for Clinical External Affairs: Jeremy Hall (Cardiff)Secretary for Non-clinical External Affairs: Paula Moran (Nottingham)

CouncilSarah Bailey (Bath)James Stone (London)Paul Stokes (London)Rachel Upthegrove (Birmingham)Ciara McCabe (Reading)Carmine Pariante (London)Angela Roberts (Cambridge)Peter Talbot (Manchester)

Past-PresidentsMax HamiltonAlec CoppenPhilip BradleyMerton SandlerEugene PaykelSusan Iversen

Malcolm LaderBrian LeonardStuart MontgomeryBarry EverittBill DeakinTrevor Robbins

David NuttCharles MarsdenGuy GoodwinClare StanfordThomas BarnesGavin Reynolds

Nicol FerrierBarbara SahakianPaul Harrison

Honorary MembersPierre BlierAlec CoppenTimothy CornSusan IversenMalcolm Lader

Paul LeberBrian LeonardEugene PaykelHannah Steinberg

Co-optedJonas Eberhard (Lundbeck)

Non-Voting Council MembersDavid Nutt (London)Editor of Journal of PsychopharmacologyHamish McAllister-Williams (Newcastle) BAP Director of Education David Baldwin (Southampton)Chair of the RCPsych Psychopharmacology Committee

Governance PanelRichard Green (Chair)Thomas BarnesEileen Joyce

6 Harrogate 2017

GENERAL INFORMATIONAnnual General Meeting: Hall D on Monday at 17:30

Applied Clinical Science Stream: Queen’s Suite 1 on Sunday at 12:00 and continues on Monday within the main conference

Blogging and Tweeting: There will be a new team of bloggers this year. The blogs will be hosted on the BAP website. If you are tweeting during the conference please use hashtag #BAP2017 to share your thoughts and feedback about sessions. Follow us on Twitter @BAPsych.

Certificates of Attendance: Will be emailed after the Conference, upon request. Certificates are also available to download from the app.

Editorial Board Meeting (JoP): Meeting room A on Tuesday at 12:45

Editorial Board Meeting (TA): Meeting room A on Tuesday at 13:45

Exhibition: Studio 1

Guest Lecture: Professor Sir Robin Murray in Hall D on Monday at 11:45

Lunch: Studio 1

Name Badges: Must be worn during all scientific sessions. BAP staff will approach anyone not wearing a badge, to verify their identity. If you lose your badge, please collect another from the BAP deskWe recycle name badge holders – please leave yours at the BAP desk before departure

Photography and Recording: Prohibited during oral sessions except by the official BAP photographersPlease seek permission from the presenters if you wish to photograph any poster presentations

Post-doctoral Symposium: Queen’s Suite 1 on Tuesday at 17:00

Posters Studio 1. Posters with odd numbers to be presented on Monday 14:00–15:30; Posters with even numbers to be presented on Tuesday 14:15–15:45

7Harrogate 2017

Pre-clinical Meeting: Queen’s Suite 2 on Sunday at 14:45

Prize-giving: 2017 Prizes and Awards will be presented at the Conference Dinner on Tuesday at the Royal Hall

Psychopharmacology Award Prize-Winners:

Oral presentations in Queen’s Suite 1 on Tuesday at 11:30

Reception and Conference Dinner:

(for those who have a ticket)The Royal Hall on Tuesday at 19:30

Refreshments: Studio 1

Registration and Information: The BAP desk will be open at the following times in theFoyer of the Queen’s Suite:

Sunday 11:00–18:30Monday 08:15–18:00Tuesday 08:15–17:30 Wednesday 08:45–12:00

Satellite Symposium: Sunday – Galen Pharma, Queen’s Suite 1 at 17:15

Short Oral Sessions: Hall D, Queen’s Suite 1 & 2 on Tuesday at 15:45

Speaker Preview Room: By Studio 1

Statistics Clinic: Studio 1

Symposia: 1, 4, 7 in Hall D2, 5, 8 in Queen’s Suite 13, 6, 9 in Queen’s Suite 2

Trainees’ Workshop: King’s Suite on Tuesday at 12:45

Welcome Reception: The Crowne Plaza on Sunday at 19:00The BAP President will give a short welcome address at 19:30

8 Harrogate 2017

2017 BAP LIFETIME ACHIEVEMENT AWARD

Professor Bill Deakin

We are delighted to announce that the 2017 Lifetime Achievement Award will be presented to Professor Bill Deakin at the Conference Dinner at the Royal Hall, Harrogate, on Tuesday, 25 July.

Bill has been a dynamic and inspirational figure in British Psychopharmacology for over 25 years, his work has international recognition and he has been a huge supporter of the BAP throughout his career.

Bill graduated in Medicine at Leeds University in 1973. During his training, he was awarded an intercalated degree in Physiology, which stimulated his interest in neurobiology and behaviour. After graduating he specialised in psychiatry, training at the Clinical Research Centre at Northwick Park, London and the National Institute for Medical Research, Mill Hill. He received his PhD in 1981 from the University of London for work on how serotoninergic pathways in the rat brain regulate adaptive responses to stress. In the early 1980s he was appointed as Senior Lecturer in Psychiatry at the University of Manchester and in 1990 he was appointed to the position of Professor of Psychiatry, going on to found the Neuroscience and Psychiatry Unit which he has headed since 1997. Bill was instrumental in setting up the Manchester Wellcome Trust Clinical Research Facility of which he was the first director.

Bill’s work has covered a wide range of areas. He has conducted research on 5HT pathways in volunteers and patients with anxiety, depression and antisocial behaviour. This established and confirmed the importance of these pathways in coping and resilience when faced with chronic difficulties as well as in addiction and social behaviour. Other work has related to the role of glutamate in schizophrenia based on post-mortem brain studies and magnetic resonance imaging. In recent years, he has conducted a series of clinical trials to investigate the role of novel agents, including the antibiotic minocycline and the anti-inflammatory drugs methotrexate and celecoxib, in improving clinical outcomes for people with schizophrenia and affective disorders.

Bill has over 200 refereed publications, an H-factor of 78 and over 20 000 citations. He has contributed many book chapters and presented at umpteen scientific meetings in the UK and abroad. Bill’s work has also involved developing clinical guidelines, including the 2012 World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of schizophrenia.

9Harrogate 2017

Bill has played an extremely important role in British neuroscience and psychopharmacology, including serving on various Medical Research Council (MRC), Wellcome Trust and National Institute for Health Research (NIHR) Panels and Strategy Committees, as well as the Royal College of Psychiatrists’ Academic Committee Task Force. He has been an NIHR Senior Investigator and experimental medicine lead of the UK Mental Health Research Network. Bill also has a prominent international presence through research collaborations and including involvement in the European College of Neuropsychopharmacology. In 2000 he was elected a Fellow of the Academy of Medical Sciences and in 2008 he was elected Foreign Corresponding Fellow of the American College of Neuropsychopharmacology (ACNP). He has been an active and inspiring promoter of psychopharmacology through teaching and conference presentations, public engagement and through supervising and mentoring many of today’s aspiring and established researchers in the field.

Bill has been a tireless and longstanding supporter of the BAP, playing a full part in its activities and regularly attending and speaking at BAP meetings and events throughout his career. He was instrumental in setting up the BAP Clinical Certificate (now in its 21st successful year) and has served both as a Council member and President (1996-99).

Warmest congratulations to Bill on behalf of the BAP Council.

10 Harrogate 2017

2017 PRIZE WINNERSBAP PSYCHOPHARMACOLOGY AWARDSTo reward excellence in non-clinical and clinical psychopharmacology.Oral presentations will be on Tuesday 25 July in Queen’s Suite 1.

Junior Non-Clinical Award: Annamaria Cattaneo (London)Senior Non-Clinical Award: Anthony Vernon (London)Senior Clinical Award: James Stone (London)

BAP PUBLIC COMMUNICATION PRIZESTo reward excellence in both clinical and non-clinical science communication to the public in the area of psychopharmacology and closely related disciplines.

Junior Prize – Anna McLaughlin (London) Senior Prize – Stephen Lawrie (Edinburgh)

Links to the winners’ public information articles are available at the BAP website.

ROBERT KERWIN INTERNATIONAL CONFERENCE BURSARIESProfessor Rob Kerwin was instrumental in advising, supporting and acting as mentor for numerous people early in their careers in psychopharmacology. To commemorate this, the Council of the British Association for Psychopharmacology introduced annual bursaries in 2008, to be awarded in his name.

Laith Alexander (Cambridge)To attend the Society for Neuroscience Meeting in WashingtonVincent Valton (London)To attend the Computational Systems Neuroscience (COSYNE) in Denver

HANNAH STEINBERG BURSARYLaunched in 2010 following a generous donation from Professor Hannah Steinberg, a founder member of the BAP, one bursary is awarded each year to support attendance at the BAP Summer Meeting by a post-graduate student who is a Training Member of BAP. The recipient this year is Joanna Oladipo (Manchester).

11Harrogate 2017

POSTER PRIZESFour Prizes will be presented to the presenters of the posters (two clinical, two non-clinical) considered most outstanding by the review committee.Professor Jo Neill will select two posters presented by BAP Training Members to receive a President’s Poster Prize.Professor Allan Young will select two posters which report psychopharmacological research directly relevant to clinical psychiatric practice to receive the RCPsych Poster Prizes.

UNDERGRADUATE AWARDSThese awards provide undergraduates with the experience of attending a national scientific meeting and encourage young psychopharmacologists to pursue a research active career. Awards are made on the basis of the abstracts, posters and summary statements from the applicants.

Decisions on the Poster Prizes and Undergraduate Awards will be made during the meeting and prizes presented at the Conference Dinner at The Royal Hall on Tuesday 25 July.

12 Harrogate 2017

BURSARIESThe Council of BAP is committed to supporting young scientists with various initiatives. For the 2017 Summer Meeting we have awarded over 40 bursaries to assist Training Members, Post-Docs and Undergraduates to attend the conference.

ACKNOWLEDGEMENTSBAP gratefully acknowledges contributions from the following, who will take part in the 2017 Summer Meeting by supporting a Satellite Symposium and/or exhibition stand.

POSTER PRESENTATIONS• All posters must be exhibited in PORTRAIT format and should remain in place for the

duration of the conference wherever possible.• Posters must be mounted with the Velcro provided.• Conference staff will remove any poster carrying a different title to that which is on the

accepted abstract.• Posters with an ODD number will be presented on Monday• Posters with an EVEN number will be presented on Tuesday• Poster Sessions: Monday 14:00–15:30 / Tuesday 14:15–15:45• Posters will also be available to view electronically on large touchscreens placed around

the hall.

ORAL PRESENTATIONSThe time allocated to each oral presentation is to allow questions from, and discussion with, the audience. This interaction is an important component of BAP Summer Meetings, reflecting our philosophy of promoting discussion and debate. Keeping to time is particularly important as attendees often wish to hear talks in different sessions. Session chairs are asked to strictly enforce the time allocated to each presenter.

SUNDAY

13Harrogate 2017

Sunday 23 July

11:00 Registration Outside Queen’s Suite

09:00 BAP Council Meeting Crowne Plaza

12:00–16:45 APPLIED CLINICAL SCIENCE STREAMDepression: Which treatment and for whom. Treatment options for treatment resistant depressionChair: Allan Young (King’s College London)

Queen’s Suite 1

12:00 Lunch

13:00 Allan Young (King’s College London)Introduction

13:15 Hamish McAllister-Williams (Newcastle University)‘Standard’ medication options and when should non-standard options be considered?

13:45 Alan Currie (Newcastle University)Medications targeting dopaminergic neurotransmission

14:05 Rupert McShane (University of Oxford)Running a ketamine treatment service in the NHS

14:25 Q&A with the Panel

14:45 Refreshments

15:15 Cindy Fu (King’s College London)tDCS

15:35 Michael Craig (King’s College London)TMS

15:55 John Rush (Duke University)VNS

16:15 Q&A with the Panel

16:45 Refreshments

All activities take place at Harrogate Convention Centre unless otherwise stated

SUNDAY

Harrogate 201714

14:45–17:00 PRE-CLINICAL WORKSHOPHow can we refine pre-clinical psychopharmacology?Chair: Paula Moran (Nottingham)

Queen’s Suite 2

14:45 Refreshments

15:00 Sarah Bailey (University of Bath)Refining everyday procedures: handling, blood sampling and injections

15:20 Anthony Vernon (King’s College London)Imaging in preclinical models as a refined approach to psychopharmacology research

15:40 Simon Bate (GlaxoSmithKline)Incorporating new statistical approaches into the design and analysis of preclinical research

16:00 Roland Jones (University of Bath)Refining animal models: epilepsy in a dish

16:20 Caroline Brennan (Queen Mary University of London)Refining animal models: drug seeking pathways in zebra fish

16:40 Discussion

17:00 End

SUNDAY

15Harrogate 2017

16:45 – 17:15 Refreshments for Satellite attendees Outside Queen’s Suite

17:15 – 18:15 SATELLITE SyMPOSIuM funded by Galen-PharmaInhaled Loxapine in Clinical PracticeSpeaker: Professor David Taylor (Maudsley Hospital, London)

Queen's Suite 1

19:00–00:00 Welcome Reception and DiscoJo Neill, President of BAP, will give a short welcome address at 19:30

Crowne Plaza

MONDAY

Harrogate 201716

Monday 24 July08:15 Registration Outside Queen’s Suite

09:00–11:30 SyMPOSIuM 1Personalized pharmacological treatments for depression: Will big data achieve what clinicians can’t?Chairs: Beata Godlewska (Oxford) and Michael Browning (Oxford)

Hall D

09:00 Rudolf Uher (Dalhousie)Will a genetic test help select treatment for individuals with depression?

S01

09:30 Neil Harrison (Brighton)Inflammation and the brain in depression: can inflammation inform treatment choices?

S02

10:00 Refreshments Studio 1

10:30 Beata Godlewska (Oxford)MRI and cognitive biomarkers in prediction of antidepressant response: big data studies

S03

11:00 Michael Browning (Oxford) Using machine learning and clinical variables to predict antidepressant response

S04

09:00–11:30 SyMPOSIuM 2The psychopharmacology of emerging calcium channel targetsChairs: Liz Tunbridge (Oxford) and Paul Harrison (Oxford)

Queen’s Suite 1

09:00 Annette Dolphin (London)Voltage gated calcium channels: a review of neuronal function and dysfunction

S05

09:30 Andrea Cipriani (Oxford) A systematic review of calcium channel antagonists in bipolar disorder, and their future potential

S06

MONDAY

17Harrogate 2017

10:00 Refreshments Studio 1

10:30 Jeremy Hall (Cardiff)Translational studies of the phenotypic effects of genetic variation in the psychiatric risk gene CACNA1C

S07

11:00 Liz Tunbridge (Oxford)Towards brain selective calcium channel antagonists for psychiatry

S08

09:00–11:30 SyMPOSIuM 3Behavioural and substance addictions: Similarities and differencesChairs: Anne Lingford-Hughes (London) and Naomi Fineberg (Hertfordshire)

Queen’s Suite 2

09:00 Sam Chamberlain (Cambridge)Cross-cutting diagnostic and neurobiological issues in behavioural addictions: a valid concept?

S09

09:30 Anna Goudriaan (Amsterdam)Neuroimaging and cognition of gambling compared with substance addiction

S10

10:00 Refreshments Studio 1

10:30 Brian Odlaug (Copenhagen)Compulsive shopping, stealing, and internet use: what do we know? What don’t we know?

S11

11:00 Jon Grant (Chicago) Evidence-based and emerging treatments for behavioural and substance addictions

S12

MONDAY

Harrogate 201718

11:45–12:30 BAP GUEST LECTURE Professor Sir Robin Murray (King’s College London)Facts about psychosis that (most) psychopharmacologists prefer to ignoreChair: Jo Neill (Manchester)

Hall D

12:45–14:00 Lunch and Poster Preview Studio 1

14:00–15:30 POSTER SESSIONSee pages 33–47 for poster detailsGroup A: Anxiety Group B: Developmental DisordersGroup C: Affective DisordersGroup D: Cognition Group E: Schizophrenia/PsychosisGroup F: Recreational Drugs and Drug Dependence

• Presenters should stand by their poster during the Monday Poster Session if it has an ODD number.

• Posters should be left in place for the duration of the conference whereever possible.

Members of the poster review panel will view the posters on both days. Poster Prizes will be awarded at the Conference Dinner on 25 July.

Studio 1

14:45–15:30 Refreshments Studio 1

MONDAY

19Harrogate 2017

15:45–17:15 SPECIAL SESSIONChallenges in managing depressionChair: Hamish McAllister-Williams (Newcastle)

Hall D

15:45 Elias Eriksson (University of Gothenburg)Challenging the perception that antidepressants don’t work

16:05 Andrea Cipriani (University of Oxford)Are there pharmacological options to reduce suicide risk?

16:25 Carmine Pariante (King’s College London)Is inflammation a viable treatment target in depression?

16:45 John Rush (Duke University)Future opportunities for the management of depression

17:30–19:00 BAP ANNUAL GENERAL MEETINGBAP Members onlyChair: Dr Mitul Mehta, Meetings Secretary

Hall D

MONDAY

Harrogate 201720

AGM Agenda

1. Presidential Address Professor Jo Neill

2. Motions for approval:

2.1 That the Minutes of the 2016 Annual General Meeting be adopted as a correct record

Professor Jo Neill

2.2 That the Editor’s Report be received Professor David Nutt

2.3 That the Trustees/Directors Annual Report and audited accounts for the period 1 January to 31 December 2016 be received and adopted

Professor Elizabeth Tunbridge

2.4 That the Honorary General Secretary’s Report be received*2.4.1 That the words “a class of Early Career Member” be inserted in clause 3(1) and the words “Early Career,” be inserted in clause 9(2) and also in clause 16(1), and the words “Full and Honorary” be deleted from clause 26.

Dr Maxine Patel

2.5 That the Governance Panel’s Report be received Professor Richard Green

3. Discussion chaired by Dr Mitul Mehta

*Articles – clauses 3(1), 9(2), 16(1) (text in bold indicates the proposed change)3(1) There shall be a class of Full Member, a class of Early Career Member, a class of Honorary Member, and a class of Retired Full Member and Members in good standing within each of these classes shall be entitled to the rights of membership including the exercise of one vote each at any general meeting9(2) A quorum is:Thirty three Full, Early Career, Honorary or Retired Full members entitled to vote upon the business to be conducted at the meeting;16(1) Subject to Articles 3 and 14 and the next paragraph, every Full, Early Career, Honorary or Retired Full member, whether an individual or an organisation shall have one vote.

*Articles – clause 2626. Existing text: All Full and Honorary members who are entitled to receive notice of a general meeting must be given not less than twenty-one clear days’ notice of any resolution to be put to the meeting to appoint a Director other than a Director who is to retire by rotation.26. Proposed text: All members who are entitled to receive notice of a general meeting must be given not less than twenty-one clear days’ notice of any resolution to be put to the meeting to appoint a Director other than a Director who is to retire by rotation.

TUESDAY

21Harrogate 2017

Tuesday 25 July08:15 Registration Outside Queen’s Suite

09:00–11:30 SyMPOSIuM 4Adverse and beneficial effects of cannabinoids – new insights from genetics and clinical trialsChairs: Marcus Munafo (Bristol) and Anthony Vernon (London)

Hall D

09:00 Marcus Munafo (Bristol)Causal effects of cannabis use on psychosis: evidence from Mendelian randomisation analyses

S13

09:30 Marta Di Forti (London)Association between polygenic risk scores, level of cannabis use and risk of psychosis

S14

10:00 Refreshments Studio 1

10:30 Gabriel Robert (Rennes) Early cannabis use, polygenic risk score for schizophrenia and brain maturation in adolescence

S15

11:00 Markus Leweke (Mannheim) Targeting the endocannabinoid system for therapeutic purposes in neuropsychiatric conditions

S16

09:00–11:30 SyMPOSIuM 5The role of brain connectivity in brain disorders and their treatmentChairs: Catherine Harmer (Oxford) and Oliver Howes (London)

Queen’s Suite 1

09:00 Trevor Robbins (Cambridge) Cortico-striatal interactions in impulsive-compulsive disorders

S17

09:30 Mary Phillips (Pittsburgh) Brain connectivity in bipolar disorder: toward a new neural model and implications for treatment

S18

TUESDAY

Harrogate 201722

10:00 Refreshments Studio 1

10:30 Michael Bloomfield (London) The effects of cannabis on brain connectivity and implications for treating cannabis dependence

S19

11:00 Ed Bullmore (Cambridge)Connectomics of schizophrenia

S20

09:00–11:30 SyMPOSIuM 6Psychopharmacology of the older and, almost certainly, degenerating brainChairs: Martien Kas (Groningen) and Hugh Marston (Eli Lilly & St Andrews)

Queen’s Suite 2

09:00 Alistair Burns (Manchester)The challenges of psychopharmacology in dementia

S21

09:30 Luca Passamonti (Cambridge)Exploring the relationship between neuropathology and symptoms

S22

10:00 Refreshments Studio 1

10:30 Jennifer Li (Eli Lilly) Reverse-translation of quantitative biology in neurodegenerative disease

S23

11:00 Martien Kas (Groningen) Developing a quantitative approach to symptomology of social withdrawal

S24

TUESDAY

23Harrogate 2017

11:30–12:30 BAP 2017 PSYCHOPHARMACOLOGY AWARD WINNERS’ ORAL PRESENTATIONS Chair: Allan Young

Queen’s Suite 1

11:30 Annamaria CattaneoFOXO1, A2M and TGFB1: three novel genes predicting depression in gene X environment interactions are identified using cross-species and cross-tissues transcriptomic and miRNomic analysesWinner of the Non-Clinical Junior Award

PW01

11:45 Anthony Vernon Neuroimaging in preclinical models as a refined approach to psychopharmacology researchWinner of the Non-Clinical Senior Award

PW02

12:00 James StoneGlutamate and Functional MRS – A Dynamic Duo?Winner of the Clinical Senior Award

PW03

12:30–14:15 Lunch and Poster Preview Studio 1

12:45–14:15 EDITORIAL BOARD MEETINGSJournal of PsychopharmacologyTherapeutic Advances in Psychopharmacology

Meeting Room A

TUESDAY

Harrogate 201724

12:45–14:15 TRAINEES’ WORKSHOP(for those who have pre-registered for the event)Organised by: Paula Moran (Nottingham) and Jeremy Hall (Cardiff) The BAP is committed to supporting the next generation of researchers.The theme for this year is “How to...”.

King’s Suite

Jeremy Hall (Cardiff)How to use fellowships to advance your career

Paul Harrison (Oxford)How to publish

Jennifer Li (Lilly)How to build a career in the pharmaceutical industry

Paula Moran (Nottingham)The loneliness of the long distance psychopharmacologist. How to interact with different scientific disciplines

14:15–15:45 POSTER SESSIONSee pages 33–47 for poster detailsGroup A: Anxiety Group B: Developmental DisordersGroup C: Affective DisordersGroup D: Cognition Group E: Schizophrenia/PsychosisGroup F: Recreational Drugs and Drug Dependence

• Presenters should stand by their poster during the Tuesday Poster Session if it has an EVEN number.

• Posters should be left in place for the duration of the conference whereever possible.

Members of the poster review panel will view the posters on both days. Poster Prizes will be awarded at the Conference Dinner on 25 July.

15:00–15:45 Refreshments Studio 1

TUESDAY

25Harrogate 2017

15:45–16:45 SHORT ORALS 1Mechanisms of anxiety and its treatmentChair: Catherine Harmer (University of Oxford)

Hall D

15:45 Shaun Kit Lung Quah (University of Cambridge)Serotonin transporter (SLC6A4) expression in the right amygdala and serotonin 2A and 2C receptor expression ratio (HTR2A:2C) in the right amygdala and dorsal anterior cingulate cortex (dACC) associates with anxious behaviour(co-authors: Santangelo AM, Roberts AC)

A10

16:00 Toby Wise (King’s College London) Neural systems underlying active avoidance behaviour in major depression(co-authors: Marwood L, Williams SCR, Cleare AJ, Perkins AM)

A15

16:15 Franziska Goer (University College London) fMRI investigation of the effect of induced anxiety on Pavlovian biases during reinforcement learning in healthy and anxious individuals(co-authors: Aylward J, Mkrtchian A, Roiser J, Robinson OJ)

A12

16:30 Martina Di Simplicio (University of Cambridge) The effect of four weeks SSRI administration on nonverbal behaviour in high and low neurotic healthy volunteers(co-authors: Warren MB, Troisi A, Harmer CJ)

C18

TUESDAY

Harrogate 201726

15:45–16:45 SHORT ORALS 2Circuits in schizophreniaChair: James Stone (King’s College London)

Queen’s Suite 1

15:45 Maddy King (University of Nottingham) Gestational poly(I:C) attenuates frontal cortical cytokine, mTOR and serotonergic responses to isolation rearing in a ‘dual-hit’ model for schizophrenia(co-authors: Shortall SE, Goh J-Y, O’Sullivan SE, Bushby K, Herbert EA, Ravat F, Shotton L, Fone KCF)

E36

16:00 Nazanin Doostdar (University of Manchester) Electrophysiological properties of the hippocampus-medial prefrontal cortex pathway in the sub-chronic phencyclidine model for schizophrenia(co-authors: Davy O, Neill JC, Gigg J)

E43

16:15 Michelle Kokkinou (Imperial College London) Midbrain dopamine neuron firing mediates the effects of ketamine treatment on locomotor activity: a DREADD experiment(co-authors: Bonsall DR, Irvine EE, Ungless MA, Withers DJ, Howes OD)

E34

16:30 Fiona Pepper (King’s College London) Hippocampal, PFC and dopamine dysfunction in first episode psychosis patients(co-authors: Kotoula V, Jauhar S, Howes O)

E02

TUESDAY

27Harrogate 2017

15:45–16:45 SHORT ORALS 3Regulation and relevance of inflammation in affective disordersChair: Carmine Pariante (King’s College London)

Queen’s Suite 2

15:45 Ruihua Hou (University of Southampton) Effects of SSRIs on peripheral inflammatory cytokines in patients with first episode generalised anxiety disorder(co-authors: Tang Z, Ye G, Chen X, Pan M, Fu J, Fu T, Liu Q, Gao Z, Baldwin SD)

A18

16:00 Nicole Mariani (King’s College London) Expression changes of inflammation-related genes in the blood mRNA of patients with depression: a study in treatment resistant, treatment responsive, or untreated patients (co-author: Cattaneo A, Malpighi C, McLaughlin AP, Nikkhleshat N, Hastings C, Nettis MA, Zajowska Z, Byrom H, Cowen P, Cavanagh J, Harrison N, Bullmore E, The Wellcome Trust Neuroimmunology of Mood Disorders and Alzheimer’s Disease, Mondelli V, Pariante CM)

C12

16:15 Shi Yu Chan (University of Oxford)Minocycline modulates hippocampal NMDA receptor signalling in a mouse inflammation model(co-authors: Burnet PWJ)

C32

16:30 Zuzanna Zajkowska (King’s College London)The role of endocannabinoids in inflammation-induced depression(co-authors: Russell A, Hepgul N, Borsini A, Forton D, Agarwal K, Zunszain PA, Mondelli V, Pariante CM)

C09

TUESDAY

Harrogate 201728

17:00–18:00 POST-DOCTORAL SYMPOSIUM Treatments in depression – new insights for an ongoing problemChair: Silke Conen and Jo Neill (University of Manchester)

Queen’s Suite 1

17:00 Becci Strawbridge (King’s College London)Predicting response to psychological treatment for depression: combining psychosocial and inflammatory markers

PD01

17:15 Liliana Capitao (University of Oxford)Early effects of fluoxetine on emotional neural processing in depressed adolescents

PD02

17:30 Muzaffer Kaser (University of Cambridge)Improving cognition in patients with remitted depression: is modafinil a feasible option?

PD03

17:45 James Rucker (King’s College London)The highs and lows of psychedelics in the treatment of depression

PD04

19:30 Reception and Conference Dinner(for those who have a ticket)

Royal Hall

TUESDAY

29Harrogate 2017

Conference Dinner Menu

Pressed rabbit terrine, summer vegetables & mustard dressing

Pan-roasted potato gnocchi, pea puree, broad bean & mint & white onion tuile (v)

Slow-cooked pork, black pudding fritter, candied apples, warm potato & celeriac salad

Home-made goats cheese ricotta & spinach ravioli, warm English beetroot salad, roasted hazelnut , tomato chervil dressing (v)

Lemon & blueberry mille feuille

Tea, coffee & mints

Followed by presentation of the 2017 Prizes and Awards and a Disco until 12:00 midnight

(The vegetarian option will be provided to those who have pre-ordered)

WEDNESDAY

Harrogate 201730

Wednesday 20 July08:45 Registration Outside Queen’s Suite

09:30–12:00 SyMPOSIuM 7Treatment of dysfunction in hot and cold cognition in mood disordersChairs: Allan Young (London) and Richard Porter (Otago)

Hall D

09:30 Allan Young (London)Targeted treatments for cognitive dysfunction in bipolar disorder

S25

10:00 Kamilla Miskowiak (Copenhagen)Neurobiological underpinnings of cognitive enhancement treatment in mood disorders

S26

10:30 Refreshments Studio 1

11:00 Catherine Harmer (Oxford) Abnormalities in emotional processing in mood disorders – novel treatments

S27

11:30 Richard Porter (Otago)Psychological treatment of cognitive abnormalities in mood disorders

S28

09:30–12:00 SyMPOSIuM 8The brain-gut-adipose axis: breaking the dichotomy between physical and mental health Chair: Valeria Mondelli (London) and Robert Yolken (Baltimore)

Queen’s Suite 1

09:30 Ted Dinan (Cork)Brain-gut-microbiota axis: a novel therapeutic target

S29

10:00 Valeria Mondelli (London) Effects of antipsychotic treatment on immune activation in the adipose tissue

S30

WEDNESDAY

31Harrogate 2017

10:30 Refreshments Studio 1

11:00 Phil Burnet (Oxford) Effects of prebiotics on the brain

S31

11:30 Robert Yolken (Baltimore)Intestinal inflammation, the microbiome, and human neuropsychiatric disorders: results of a randomized trial of a probiotic prepartation for the prevention of mania

S32

09:30–12:00 SyMPOSIuM 9Biomarkers of treatment response for schizophrenia and bipolar affective disorder: Latest updatesChairs: Oliver Howes (London) and Paula Moran (Nottingham)

Queen’s Suite 2

09:30 Jo Neill (Manchester)Markers of potential therapeutic efficacy for negative and cognitive symptoms

S33

10:00 Matej Oresic (Turku)Metabolomics approach to study the development of metabolic co-morbidities in first-episode psychosis

S34

10:30 Refreshments Studio 1

11:00 James Walters (Cardiff) Exploring the genetics of treatment resistance in schizophrenia

S35

11:30 Oliver Howes (London)The transdiagnostic neurobiology of psychosis and treatment response: PET and MRI imaging findings in schizophrenia and bipolar affective disorder

S36

12:00 End of the 2017 Summer Meeting

Join us for the Summer Meeting in London, 22–25 July 2018

32 Harrogate 2017

2018 SUMMER MEETINGMeet us at Imperial College London for the 2018 Summer Meeting 22–25 JulySymposia to include:

• Early intervention for the next generation: Therapeutic challenges in youth mental health • Mineralocorticoid/ glucocorticoid receptor imbalance and early life stress as risk factors

for affective disorders• PTSD; Exposure to traumatic events, brain changes and current and novel treatments • Microglia role in neuropsychiatric disease and its potential as a treatment target • New concepts in the co-morbidity of psychiatric disorders, eating disorders and obesity • Risk factors for autism and schizophrenia: Convergence or divergence? • The opiate system in addiction: latest findings from substance and behavioural addictions • Bridging the translational gap in psychiatry: a role for neuronal oscillations?• Towards a mechanistic understanding of anxiety disorders: translational, pharmacological,

neural and computational perspectives

Short Orals, Satellite Symposia, Special Sessions, Post-Doc Symposium

Conference dinner at the Royal Garden Hotel, Kensington

Details will be posted on the website as they become available

www.bap.org.uk/BAP2018

POSTER GROUPS

33Harrogate 2017

GROUP A: ANXIETY

This abstract has been withdrawn A01

Investigating the effects of gender on anxiety-related behaviour evoked by kappa opioid receptor activation in the elevated plus mazeLalji HM, Bailey SJ, Bailey CP, Almatroudi A

A02

Stress-induced anxiety is not reversed by histaminergic precursor chronic treatment in C57BL/6J mice Daher F, Padovan CM, Mattioli R

A03

Activation of 5-HT7 receptors localized in the median raphe nucleus are involved in the disconnection of stressful memories in rats Padovan CM, Lopes WL, Zuelli FMGC

A04

CACNA1C dysfunction: the impact on adult neurogenesis Moon AL, Hall J, Thomas KL, Brydges N, Haan N

A05

Neurodevelopmental and behavioural consequences of maternal immune activation in male and female Wistar rats Oladipo JM, Fasolino V, Edye ME, Doostdar N, Podda G, Manca M, Miyan J, Neill JC

A06

Glucocorticoid Receptor and its modulator FKBP51 mRNA expressions are downregulated in an experimental model of early-life adversity associated with psychopathologies Juruena MF, Umeoka E, Umeoka MSS, Antunes-Rodrigues J, Garcia-Cairasco N, Mello MF

A07

The impact of induced and unmedicated pathological anxiety on a back-translated measure of negative bias Aylward J, Robinson OJ

A08

Using an online personality questionnaire for rapid recruitment of hard to find participants in pharmacological researchPatrick F, Higgens-Stockden F, Young AH, Perkins AM

A09

Serotonin transporter (SLC6A4) expression in the right amygdala and serotonin 2A and 2C receptor expression ratio (HTR2A:2C) in the right amygdala and dorsal anterior cingulate cortex (dACC) associates with anxious behaviourQuah SKL, Santangelo AM, Roberts ACThis will also be presented as a Short Oral on Tuesday afternoon

A10

Evaluating the anxiolytic potential of ibuprofen in the 7.5% carbon dioxide experimental model of anxiety Barnes JW, Taylor ANW, Board A, Bell R, Hilton S, Mekhail I, Kok JJC, Baldwin DS, Garner M

A11

POSTER GROUPS

Harrogate 201734

fMRI investigation of the effect of induced anxiety on Pavlovian biases during reinforcement learning in healthy and anxious individuals Goer FK, Aylward J, Mkrtchian A, Roiser J, Robinson OJThis will also be presented as a Short Oral on Tuesday afternoon

A12

The psychological and physiological effects of a novel virtual reality stressor Martens MAG, Antley A, Pomes A, Slater M, Freeman D, Tunbridge EM, Harrison PJ

A13

Neurometabolites in anterior cingulate cortex in chronic fatigue syndrome: A magnetic resonance spectroscopy study at 7 Tesla Chen C, Godlewska BR, Emir U, Angus B, Andersson M, Cowen PJ

A14

Neural systems underlying active avoidance behaviour in major depression Wise T, Marwood L, Williams SCR, Cleare AJ, Perkins AMThis will also be presented as a Short Oral on Tuesday afternoon

A15

Belief about treatment allocation predicts placebo response in the 7.5% carbon dioxide model of anxiety Huneke NTM, Bamford S, Baldwin DS, Garner M

A16

Concomitant prescriptions of tramadol or pregabalin with antidepressant drugs in a pain service outpatient clinic: a retrospective cross-sectional case-note study Mutta E, Miorelli A, Price C, Baldwin DS

A17

Effects of SSRIs on peripheral inflammatory cytokines in patients with first episode generalised anxiety disorder Hou R, Tang Z, Ye G, Chen X, Pan M, Fu J, Fu T, Liu Q, Gao Z, Baldwin SDThis will also be presented as a Short Oral on Tuesday afternoon

A18

GROUP B: DEVELOPMENTAL DISORDERS

Modulating catecholaminergic neurons in the 5-choice serial reaction time task using designer receptors exclusively activated by designer drugs (DREADDs) Fitzpatrick CF, Runegaard AH, Christiansen SH, Navntoft C, Woldbye DW, Gether U, Andreasen JT

B01

Effects of amphetamine and DOI on impulsive action in the 5-choice serial reaction time task Fitzpatrick CM, Maric VS, Andreasen JT

B02

Assessing attention & impulsivity in a putative model of ADHD Fitzpatrick CF, McGirr J, Rickhag M, Gether U, Andreasen JT

B03

POSTER GROUPS

35Harrogate 2017

This abstract has been withdrawn B04

ADHD and stimulant medication disrupt the temporal lag structure within default mode and salience networks Clarke CL, Sethi A, Cercignani M, Harrison NA

B05

Dopaminergic modulation of cognition in adults with attention-deficit hyperactivity disorder (ADHD) Hook RH, Muller U, Ioannidis K, Isobe M, Grant J, Chamberlain SR, Myklebust S

B06

The neurofunctional correlates of time discrimination in young adults with autism spectrum disorder, attention-deficit/hyperactivity disorder and the comorbid condition Lukito S, O’Daly O, Lythgoe DJ, Whitwell S, Debnam A, Simonoff E, Rubia K

B07

Default mode network connectivity in adolescents with conduct disorder and varying levels of attention-deficit/hyperactivity disorder symptomsBroulidakis MJ, Fairchild G, Sully K, Blumensath T, Darekar A, Sonuga-Barke EJ

B08

Computerised cognitive remediation therapy in adults with ADHD: preliminary study Tomlinson A, Baskind R, Johnson J, Neill JC

B09

Shared and disorder-specific neurocomputational mechanisms of decision-making in autism spectrum disorder and obsessive-compulsive disorder Carlisi CO, Norman LJ, Murphy CM, Christakou A, Chantiluke K, Giampietro V, Simmons A, Brammer M, Murphy DM, Mataix-Cols D, Rubia K

B10

Using wearable sensor technology to manage EBAD (emotional, behavioural and autonomic dysregulation) in patients with complex neurodevelopment disorders Santosh PJ, Sagar-Ouriaghli I, Fiori F, Singh J

B11

GROUP C: AFFECTIVE DISORDERS

FOXO1, A2M and TGFB1: three novel genes predicting depression in gene X environment interactions are identified using cross-species and cross-tissues transcriptomic and miRNomic analyses Cattaneo A, Cattane N, Czamara D, Eriksson J, Kajantie E, Luoni A, Malpighi C, Suarez A, Lahti J, Mondelli V , Dazzan P, Räikkönen K, Binder E, Riva MA, Pariante CM

C01

Associations between polygenic risk scores for five psychiatric illnesses and brain structure using multivariate pattern recognitionRanlund S, Rosa MJ, de Jong S, Cole J, Fu C, Frangou S, Mehta MA, Dima D

C02

POSTER GROUPS

Harrogate 201736

Evidence of a sex-specific effect of calcium voltage-gated channel subunit alpha 1 C (CACNA1C) single nucleotide polymorphisms on mood disorder phenotypes within two population cohorts Ferguson A, Ward J, Graham N, Pell J, Bailey M, Smith DJ, Lyall D

C03

Genome-wide analysis Of 113,968 individuals in UK biobank identifies four loci associated with mood instability Ward J, Strawbridge R, Graham N, Bailey M, Ferguson A, Lyall D, Cullen B, Pidgeon L, Cavanagh J, Mackay D, Pell J, O’Donovan M, Escott-Price V, Smith D

C04

A meta-analysis of reward processing differences between depressed and healthy individuals Halahakoon DC, Roiser JP

C05

Atypical depression and non-atypical depression: is HPA axis function a biomarker? A systematic reviewJuruena MF, Bocharova M, Agustini B, Young AH

C06

Early onset of lithium relapse prevention in bipolar disorder Taylor MJ

C07

Serum factors as predictors of interferon-alpha (IFN-α)-induced depression Borsini A, Hepgul N, Russell A, Zajkowska Z, Zunszain PA, Pariante CM, Thuret S

C08

The role of endocannabinoids in inflammation-induced depressionZajkowska Z, Russell A, Hepgul N, Borsini A, Forton D, Agarwal K, Zunszain PA, Mondelli V, Pariante CMThis will also be presented as a Short Oral on Tuesday afternoon

C09

The role of cardiovascular associated inflammatory markers in development of depression Nikkheslat N, Zunszain PA, Tylee A, Carvalho LA, Pariante CM

C10

Investigating the link between childhood trauma, cortisol levels, inflammation, and response to treatment in patients with depressionMcLaughlin AM, Nikkhleshat N, Hastings C, Nettis MA, Zajowska Z, Mariani N, Wellcome Trust Neuroinflammation Consortium BIODEP, Cowen C, Cavanagh C, Harrison N, Bullmore E, Pariante CM, Mondelli V

C11

Expression changes of inflammation-related genes in the blood mRNA of patients with depression: a study in treatment resistant, treatment responsive, or untreated patients Mariani N, Cattaneo A, Malpighi C, McLaughlin AP, Nikkhleshat N, Hastings C, Nettis MA, Zajowska Z, Byrom H, Cowen P, Cavanagh J, Harrison N, Bullmore E, The Wellcome Trust Neuroimmunology of Mood Disorders and Alzheimer’s Disease, Mondelli V, Pariante CMThis will also be presented as a Short Oral on Tuesday afternoon

C12

POSTER GROUPS

37Harrogate 2017

The role of cortisol levels in the response to antiglucocorticoid treatment in patients with mood disorders: a systematic review Lombardo G, Gianotti L, Pariante CM, Mondelli V

C13

Effects of SSRIs on inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis Hou R, Wang L, Wang R, Qiao D, Baldwin DS

C14

A systematic review of anti-inflammatory agents in the treatment of mood disorders Hou R, Cheng X, Li R, Yang Y, Liu J, Zhang J, Baldwin DS

C15

‘Serotonin syndrome’ with tramadol alone and in combination with SSRI/SNRI antidepressants Mills S, Huneke NTM, Baldwin DS

C16

Efficacy and safety of lurasidone in children and adolescent patients with bipolar I depression Goldman R, DelBello MP, Deng L, Cucchiaro J, Loebel A

C17

The effect of four weeks SSRI administration on nonverbal behaviour in high and low neurotic healthy volunteers Di Simplicio M, Warren MB, Troisi A, Harmer CJThis will also be presented as a Short Oral on Tuesday afternoon

C18

This abstract has been withdrawn C19

Dose-dependent effects of ketamine and norketamine on brain perfusion in healthy volunteers de Rover M, van Osch MJ, Dahan A, Niesters M

C20

The effect of a transdermal scopolamine patch on emotional processing Bukala BR, Browning M, Cowen PJ, Murphy SE, Harmer CJ

C21

A pilot audit of antidepressant switching in a community mental health teamHodgson RE, Eboka YM

C22

The effects of adjunctive minocycline therapy in treatment resistant depression (MINDEP) Hastings C, McLaughlin A, Nettis MA, Nikkheslat N, Zajkowska Z, Young A, Cleare A, Pariante C, Mondelli V

C23

Influence of baseline GABA on reward prediction error in healthy and depressed individuals Kumar PK, Jensen JE, Bachetti JLB, Yiang JY, Pizzagalli DAP

C24

Glutamatergic system and depression: an MRS 7 Tesla study in medication-free depressed patientsGodlewska BR, Emir U, Sharpley A, Masaki C, Cowen PJ

C25

POSTER GROUPS

Harrogate 201738

Dissociable temporal effects of bupropion on behavioural measures of emotional and reward processing in major depressive disorder Walsh AEL, Michael B, Drevets WC, Furey M, Harmer CJ

C26

Wistar Kyoto vs. Sprague Dawley rats in the delayed non-match to sample task: effects of ketamine and pregnenolone-methyl-ether (PME)Sokolowska E, McDonnell CW, Rouine J, DiCapua G, Prenderville JA, Bianchi M

C27

Restraint stress-induced deficits on exploratory activity are attenuated by facilitation of 5HT7 receptors in the Median Raphe nucleus of ratsPadovan CM, Daher F, Lopes WL, Zuelli FMGC

C28

Possible involvement of the mammalian target of rapamycin (mTOR) signaling pathway in the antidepressant-like effect of agmatine as a novel endogenous neuromodulator Sahin Ozkartal C, Aricioglu F, Tuzun E, Keles R, Kucukali CI

C29

Pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 in a translational human dexamphetamine challenge model van der Aart J, Recourt K, Jacobs G, de Kam M, Khoshchin M, Kanhai K, Siebenga P, Zuiker Z, Vets E, Timmers M, de Boer P, van Gerven J

C30

Microtubular proteins as plasma biomarkers of ketamine antidepressant efficacy – a time course study in the rat Fisher AD, Rouine J, McDonnell C, DiCapua G, Prenderville JA, Bianchi M

C31

Minocycline modulates hippocampal NMDA receptor signalling in a mouse inflammation model Chan SY, Burnet PWJThis will also be presented as a Short Oral on Tuesday afternoon

C32

Alterations in plasma cytokine expression at baseline and following acute stress in ‘depressed’ Wistar-Kyoto ratsBurke T, Prenderville J, McDonnell CW, Rouine J, Bianchi M

C33

Investigating the effects of D-alanine on ACTH secretion and signalling proteins in AtT20 pituitary cells Naidoo K, Burnet PWJ

C34

Clinical correlates of cognitive impairment in patients with euthymic bipolar disorder Guillotte C, Tsapekos D, Strawbridge R, Mantingh T, Hodsoll J, Macritchie K, Stokes P, Wykes T, Young AH

C35

Neural activation in major depression disorder using a fMRI probabilistic reinforcement learning taskAntonesei A, Murayama K, McCabe C

C36

POSTER GROUPS

39Harrogate 2017

Characterising and engaging computational targets relevant to depression Pulcu E, Browning M

C37

Neural and clinical effects of prefrontal cortex stimulation to enhance psychotherapy in depression: a double-blind randomized controlled trial Nord CL, Halahakoon DC, Limbachya T, Gray A, Charpentier CJ, Lally N, Aylward J, Pilling S, Roiser JP

C38

A randomised, controlled trial assessing the effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder and healthy first-degree relatives Ott CV, Vinberg M, Bowie C, Kessing LV, Miskowiak KW, Christensen EM

C39

The association between sleep and cognitive abnormalities in bipolar disorderMcAllister-Williams RH, Bradley AJ, Gallagher P, Anderson KN

C40

Responses to social feedback in individuals with depression symptoms Frey AL, Cooney S, Copeman B, McCabe C

C41

Impact of maternal history of childhood abuse on neonatal social interaction: the mediating role of foetal development Sawyer K, Sethna V, Conroy S, Pawlby S, Sundaresh S, Biaggi A, Hazelgrove K, Osborne S, Pariante CM

C42

Antenatal depression impairs mother-infant interaction at 12 months Bind RH, Biaggi A, Hazelgrove K, Osborne S, Fantini E, Conroy S, Sethna V, Pawlby S, Pariante CM

C43

Antenatal depression and mentalization in mother-infant interaction at 12 monthsAllegri B, Sethna V, Bind R, Mattock H, Tomasetti L, Biaggi A, Hazelgrove K, Osborne S, Fantini E, Conroy S, Pawlby S, Pariante CM

C44

Chronic pain as a factor that may worsen depressive disorderMacedo BBD, Menezes IC, Baes CVW, Juruena MF

C45

Impact of major depression on cardiovascular outcomes for individuals with hypertension: prospective study in UK Biobank Graham NA, Ward J, Ward DJ, Padmanabhan S, Cavanagh J, Pell J, Mackay D

C46

Depressive symptoms are more severe in patients with chronic pain Juruena MF, Macedo BBD, Menezes IC, Baes CVW

C47

The presence of early-life stress and its subtypes raises the suicide ideation scores of bipolar patients when compared to unipolar patients Menezes IC, Baes CVW, Macedo BBD, Cleare AJ, Young AH, Juruena MF

C48

POSTER GROUPS

Harrogate 201740

GROUP D: COGNITION

Tracking behavioural changes following induction of olfactory bulbar α-synucleinopathy in mice Travaglio M, Blackmore T, Loomis S, Eaton J, Gilmour G, Marston H

D01

Induction of Cacna1c hypofunction in ketamine-activated brain networks impairs memory consolidation and alters cerebral metabolism Dawson N, Hughes R, Willi C, Whittingham-Dowd J, Bristow G

D02

Cerebrovascular changes in a mouse model of Alzheimer’s disease following lipopolysaccharide (LPS) treatmentCuli N, Agostini A, Serres S, Pardon MC

D03

The Wistar Kyoto rat displays a number of cognitive deficits, some of which are sex-specificDoherty H, Kelly JK

D04

Investigation into episodic memory deficits in an animal model for schizophreniaLambert SL, Neill JC, Gigg J

D05

Opening the file drawer on failures in experimental habit induction Gillan CM, de Wit S, Kindt M, Knot S, Verhoeven AAC, Robbins TW, Gasull J, Evans M, Mirza H, Gillan CM

D06

Evaluation of a short, robust fMRI control task for pharmacological fMRI studies Harvey-Cox JL, Demetriou L, Wall MB

D07

Cognitive bias modification of face emotion perception: a randomised controlled trial of transference to cognitive and self-report measures in healthy volunteersPeters SE, Lumsden J, Peh OH, Penton-Voak IS, Munafò MR, Robinson OJ

D08

Dissecting contributions to anhedonia from motivation to exert physical effort for rewards: a computational analysis of behaviour Valton V, Gray A, VanUrk S, Payne MEM, Roiser JP

D09

Rewards and punishments differently affect motivation to exert cognitive effortMkrtchian A, Valton V, Roiser JP

D10

A causal role for noradrenaline in controlling the influence of prior beliefs during decision making: a double-blind, placebo-controlled studyLawson RP, Bisby J, Imber S, Burgess N, Rees G

D11

The long term effects of MDMA on empathy: does MDMA enhance feelings of emotional empathy? Kosmider S

D12

POSTER GROUPS

41Harrogate 2017

MDMA increases activity of social brain areas and cooperative responses when interacting with trustworthy players during an iterated Prisoner’s Dilemma Gabay AS, Kempton MJ, Mehta MA

D13

Understanding cognitive functions related to driving following kava (Piper methysticum) use at traditional consumption volumes Aporosa A

D14

Is impaired response control whilst drinking alcohol due to impaired attention? Stevens T, Morgan CJA, McAndrew A, Carlyle M

D15

The effects of Delta-9-Tetrahydrocannabinol (THC) on hippocampal memory function: a systemic review Petrilli K, Lees R, Hindocha C, Howes O, Curran V, Freeman T, Bloomfield M

D16

Action and belief update in an unstable environment in obsessive-compulsive disorder Vaghi MM, Luyckx F, Sule A, Fineberg NA, Robbins TW, De Martino B

D17

Does N-acetylcysteine affect measures of compulsivity in an eating-disorder risk group? Pike AC, Sharpley AL, Williams C, Park RJ, Cowen PJ

D18

GROUP E: SCHIZOPHRENIA/PSYCHOSIS

GABAA receptor availability in patients with schizophrenia: a PET study using [11C]-Ro15 Reis Marques T, Veronese M, Rabiner I, Turkheimer FE, Howes OD

E01

Hippocampal, PFC and dopamine dysfunction in first episode psychosis patients Pepper F, Kotoula V, Jauhar S, Howes OThis will also be presented as a Short Oral on Tuesday afternoon

E02

A test of the trans-diagnostic dopamine hypothesis of psychosis: a PET study in bipolar affective disorder and comparison with schizophrenia Jauhar S, Nour M, Veronese M, Rogdaki M, Turkheimer F, Bonoldi I, Azis M, McGuire PK, Howes OD

E03

First experience of measuring glutamate synthesis in vivo in schizophrenia using 13C-magnetic resonance spectroscopy (MRS) Gregory CJ, Anton A, Lanz B, Chen C, Zhao S, Simpson EJ, Katshu MZUH, Rathnaiah M, Smallman RP, Liddle PF, Conen S, MacDonald IA, Morris PG, Williams SR, Deakin JFW

E04

POSTER GROUPS

Harrogate 201742

Auditory verbal hallucinations in first episode psychosis – an fMRI symptom capture studyDunne TF, Mallikarjun PK, Reniers R, Farmah B, Broome M, Oyebode F, Wood S, Upthegrove R

E05

Mu- opioid receptor availability in schizophrenia patients with negative symptom: A positron emission tomographic study using [11C]-carfentanil Ashok AH, Marques TR, Rabiner EA, Howes OD

E06

A placebo-controlled study of the acute effects of cannabis on psychotic-like symptoms in adolescents and adults Mokrysz C, Shaban N, Freeman TP, Curran HV

E07

Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study Tocco M, Correll C, Arango C, Goldman R, Cucchiaro J, Deng L, Loebel A

E08

Effectiveness of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study Tocco M, Arango C, Correll C, Goldman R, Cucchiaro J, Deng L, Loebel A

E09

Clinical and economic outcomes with paliperidone and aripiprazole long acting in clinical practice Hodgson RE

E10

Differential effects of antipsychotic exposure across stages of reward processing in a placebo controlled designHawkins PCT, Vernon AC, Mehta MA

E11

Paliperidone long-acting injection: one-year outcomes in clinical practice Deslandes PN, Ward E, Norris K, Sewell RDE

E12

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: the AMICUS studyBarnes TRE, Leeson V, Paton C, Marston L, Osborn DP, Kumar R, Keown P, Zafar R, Iqbal K, Singh V, Fridrich P, Fitzgerald Z, Bagalkote H, Haddad PM, Husni M, Amos T

E13

Audit on baseline monitoring serum prolactin Jayakumar A, Krishnan V

E14

Treatment of depression in schizophrenia: importance and therapeutic challenges Gregory A, Mallikarjun P, Upthegrove RA

E15

Increased DNA methylation at a transcription factor binding site in the gene for the 5-HT1A receptor correlates with negative symptoms in first episode patientsReynolds GP, Fachim HA, Tang H, Zeng L, Yang JZ

E16

POSTER GROUPS

43Harrogate 2017

Inflammatory markers’ role in screening for physical comorbidities in patients at First Episode of PsychosisNettis MA, Kolliakou A, O’Connor J, Bonaccorso S, Gardner-Sood P, David A, Gaughran F, Pariante CM, Murray R, Dazzan P, Mondelli V

E17

The effects of Δ9-tetrahydrocannabinol (THC) on emotional processing: a systematic review Lees RH, Petrilli K, Hindocha C, Howes O, Curran V, Freeman T, Bloomfield M

E18

Immune dysfunction, depressive and negative symptoms in schizophrenia Krynicki CR, Upthegrove R, Nikkheslat N, Giordano A, Pariante CM , Deakin JFW, Dazzan P

E19

Interactive effects of early life stress and CACNA1C genotype on cortisol awakening response Klaus K, Butler K, Gutierrez H, Durrant SJ, Pennington K

E20

(POMH-UK) Topic on prescribing antipsychotics for children and adolescents Gupta V, Hegarty A

E21

What does augment the risk to use cannabis on an everyday-basis in psychotic patients? Ferraro L, DiForti M, Capuccio V, Quattrone D, Tripoli G, Seminerio F, Sartorio C, Sideli L, La Cascia C, La Barbera D, Murray RM

E22

HPA-axis function differs in clinical and non-help-seeking populations with auditory verbal hallucinations Baumeister D, Chadwick P, Howes O, Peters E

E23

Differential involvement of oxytocin and V1A receptors in the thermoregulatory, sedative and prosocial effects of oxytocin in the rat Fone KCF, Williams S, Edwards A, King MV

E24

The GLP1-R agonist Liraglutide improves cognition and restores brain metabolism in Neurexin-1 α heterozygous mice. Whittingham-Dowd JK, Hughes R, Bristow G, Clapcote SJ, Dawson N

E25

Effect of nicotinic alpha 7 receptor agonist and possitive allosteric modulators on cognitive symptoms in subchronic MK-801 model of schizophrenia in rats Unal G, Aricioglu F, Hazar-Yavuz AN, Zortul H

E26

Dysregulated GABAergic expression in rodent Cyfip1+/- KO models, but not in other genetic or neurodevelopmental models of risk for psychiatric illness Trent S, Best C, Storan M, Moon A, Hall J

E27

POSTER GROUPS

Harrogate 201744

Genetic deletion of GPR88 receptors modifies the influence of amphetamine, DA agonists and PCP upon locomotor behaviour in mice Thomson DM, Mitchell EJ , Mannoury la Cour C, Millan MJ , Pratt JA, Morris BJ

E28

Synaptophysin and synaptic density in schizophrenia: a meta-analysis of post-mortem data Osimo EF, Beck K, ReisMarques T, Howes OD

E29

In vitro modulation of rodent and human neocortical gamma oscillations by a novel Kv3 channel modulator Modebadze T, Gillougley C, Alvaro GS, Large CH, LeBeau FE, Cunningham MO

E30

Aerobic exercise reverses cognitive deficits in the sub-chronic phencyclidine rat model for schizophrenia, role of brain-derived neurotrophic factor Gonzalez AJ, Heaney LM, Podda G, Oladipo JM, Grayson B, Harte MK, Large C, Neill JC

E31

Effects of phencyclidine in social groups of adolescent rats monitored in the home cage Mitchell EJ, Brett RR, Armstrong JD, Pratt JA

E32

GPR52 is a key regulator of striatal signalling and function Langmead CJ, Spark DL, Sarwar M, Stewart GD, Nithianantharajah J

E33

Midbrain dopamine neuron firing mediates the effects of ketamine treatment on locomotor activity: a DREADD experimentKokkinou M, Bonsall DR, Irvine EE, Ungless MA, Withers DJ, Howes ODThis will also be presented as a Short Oral on Tuesday afternoon

E34

Oxytocin enhances pro-social behaviour, attenuates PCP-induced hyperactivity and increases dopamine overflow in the nucleus accumbens in the ratKohli S, Edwards A, Alberati D, Ballard TM, Steward LJ, King MV, Fone KCF

E35

Gestational poly(I:C) attenuates frontal cortical cytokine, mTOR and serotonergic responses to isolation rearing in a ‘dual-hit’ model for schizophreniaKing MV, Shortall SE, Goh J-Y, O’Sullivan SE, Bushby K, Herbert EA, Ravat F, Shotton L, Fone KCFThis will also be presented as a Short Oral on Tuesday afternoon

E36

Prebiotic intake attenuates olanzapine-mediated weight gain in rats without compromising central effects Kao A, Lennox B, Burnet PW

E37

Neurexin-1 hypofunction extends life span, ameliorates behavioural senescence and alters sleep structure in Drosophila melanogaster Hughes RB, Broughton S, Dawson N

E38

POSTER GROUPS

45Harrogate 2017

Haploinsufficiency of schizophrenia risk gene Cyfip1 increases adult hippocampal neurogenesis through increased neuronal survival Haan N, Westacott L, Carter J, Hall J, Wilkinson L

E39

Cognitive and social behaviour deficits at adulthood in female rat offspring of Poly I:C treated rat dams, a developmental model for schizophrenia Grayson B, Fasolino V, Edye M, Oladipo J, Idris N, Harte MK, Neill JC

E40

Maternal poly(I:C) injection followed by post-weaning isolation rearing of rats: optimisation of a novel ‘dual-hit’ neurodevelopmental model for schizophrenia Goh J-Y, Fone KCF, King MV

E41

Translational alterations in gene expression of GABAergic markers in schizophrenia and in rats undergoing isolation rearing from weaning Fachim HA, Loureiro CM, Corsi-Zuelli FMG, Louzada- Junior P, Menezes PR, Joca SR, Reynolds GP, Shuhama R, Del-Ben CM

E42

Electrophysiological properties of the hippocampus-medial prefrontal cortex pathway in the sub-chronic phencyclidine model for schizophrenia Doostdar N, Davy O, Neill JC, Gigg JThis will also be presented as a Short Oral on Tuesday afternoon

E43

Locomotor deficits in a 16p11.2 duplication mouse model are reversed by minocycline Bristow GC, Thomson DM, Pratt JA, Morris BJ, Dawson N

E44

GROUP F: RECREATIONAL DRUGS AND DRUG DEPENDENCE

Comparison of resting-state fMRI data from multiple drug studies using multi-voxel pattern analysis: Striatal networksKowalczyk OS, Gall A, Verneuil T, Demetriou L, Roseman L, de Simoni S, Nutt DJ, Curran HV, Mehta MA, Carhart-Harris R, Wall MB

F01

Serotonin depletion lessens the benefit of motivationally salient feedback to guide behaviour in males Kanen JW, Apergis-Schoute AM, van der Flier FE, Yellowlees R, Arntz FE, Price A, Cardinal RN, Christmas DM, Sahakian BJ, Robbins TW

F02

Using baclofen to explore GABA-B receptor function in abstinent alcohol dependent and healthy volunteers: insights from pharmacokinetic and pharmacodynamic measures. Durant CF, Turton S, Jones T, Nahar LK, Cordero RE, Paterson S, Nutt DJ, Wilson SJ, Lingford-Hughes AR

F03

POSTER GROUPS

Harrogate 201746

NK1 antagonism attenuates blunted response to monetary reward anticipation in abstinent alcohol dependence Paterson LM, McGonigle J, Murphy A, Elliott R, Ersche KD, Flechais R, Orban C, Smith DG, Suckling J, Taylor EM, Deakin JFW, Robbins TW, Nutt DJ, Lingford-Hughes AR

F04

Reward deficiency in addiction: striatal blunting to monetary reward as a marker of recovery instability Paterson LM, McGonigle J, Giribaldi B, Elliott R, Ersche KD, Flechais R, Orban C, Murphy A, Smith DG, Suckling J, Taylor EM, Deakin JFW, Robbins TW, Nutt DJ, Lingford-Hughes AR

F05

Comparison of resting-state fMRI data from multiple drug studies using multi-voxel pattern analysis: Cortical networksVerneuil T, Gall A, Kowalczyk OS, Demetriou L, Roseman L, de Simoni S, Curran HV, Nutt DJ, Mehta MA, Carhart-Harris R, Wall MB

F06

Blunted amphetamine-induced opioid release in individuals with gambling disorder or alcohol dependence compared with healthy volunteers: a [11C]carfentanil PET studyTurton S, Mick I, Myers J, Colasanti A, Bowden-Jones H, Clark L, Rabiner EA, Gunn RN, Nutt DJ, Lingford-Hughes A

F07

Association of methamphetamine dependence with a genetic variant of GRIA3 gene and its interaction with a functional BDNF polymorphism Iamjan SA, Thanoi S, Watiktinkorn P, Reynolds GP, Nudmamud-Thanoi S

F08

Motivational processing of cigarette and music reward in dependent and occasional smokers: an fMRI and behavioural study Lawn W, Freeman TP, Bisby JA, Dodds CM, Curran HV, Morgan CJA

F09

The effects of long-term MDMA use on responses to social exclusionCarlyle M, Stevens T, Morgan CJA

F10

Using the NMDA receptor antagonist nitrous oxide to probe the parameters determining cue-alcohol memory destabilisation in heavy drinkers Walsh KH, Das RK, Hannaford JR, Kamboj SK

F11

Quantifying violent crime associated with alcohol use among a large cohort of sanctioned offenders in England and Wales McGrath E, Lightowlers C, Pierce M, Millar T

F12

Hospital attendance and admission as an opportunity to engage patients with alcohol use disorders Chambers SE, Baldwin DS, Lo R, Williams S, Sinclair JMA

F13

Ultra-brief mindfulness training reduces alcohol consumption in at-risk drinkers: a randomised double-blind active-controlled experiment Thomas ET, Kamboj SK, Irez D, Serfaty S, Das RK, Freeman TP

F14

POSTER GROUPS

47Harrogate 2017

Development of a brief compassion training to assist opiate addiction recoveryRockliff H, Carlyle M, Karl A, Edwards R, Morgan C

F15

Anatomy of a joint: comparing self-reported and actual dose of cannabis and tobacco in a joint, and how these are influenced by controlled acute administrationHindocha C, Freeman TP, Curran HV

F16

Cannabis potency and cannabis use disorders: a cross-sectional study indexing cannabinoids and their metabolites in cannabis, urine and hairFreeman TP, Morgan CJ, Hindocha C, Shaban N, Das RK, Curran HV

F17

Making healthier food choices: examining the contribution of goal-directed and habitual decision systems to food selectionZiauddeen H, Medic N, Forwood SE, Ahern AL, Davies KM, Jebb SA, Marteau TM, Fletcher PC

F18

Effects of stimulants on the human dopamine system: a meta-analysis and implications for drug development and preclinical models Ashok AH, Mizuno Y, Volkow ND, Howes OD

F19

Gender differences in kappa opioid receptor activated brain networks implicated in the response to stress and drugs of abuse Ma Q, Wonnacott SW, Bailey SJ, Bailey CP

F20

Imipramine attenuates the behavioural effects induced by abstinence to chronic ethanol consumptionPadovan CM, Tirapelli CR, Cardoso RC

F21

Repeat ketamine exposure induces microstructural changes in mouse brain tissue Chesters RC, Wood TC, Vernon AC

F22

Dissociation of conditioned place preference and tolerance to sucrose in planaria Mohammed Jawad RA, Prados J, Hutchinson C

F23

48 Harrogate 2017

BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY

The BAP is a learned society and registered charity. It promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry.

MembershipMembership of BAP is open to any qualified worker in a discipline relevant to psychopharmacology. Existing members include pharmacologists, psychiatrists, psychologists, neurobiologists and pharmacists.

Full Membership: Applicants are eligible for Full Membership if they can demonstrate involvement in areas relevant to psychopharmacology by, for example, qualifications, publications or research activity.

Early Career Membership: Designed to support early career scientists, such as post-doctorates, as well as clinical psychologist trainees and medical doctors in clinical training posts or clinical junior training fellowships (with PhD awarded). Those with university posts which are below the status of Lecturer, such as research assistant or research associate shall also be considered. Early Career Membership is limited to a maximum 6-year term or until they attain a change in status to Lecturer or completion of clinical training, whichever is earliest.

Training Membership: BAP aims to support professionals training in psychopharmacology and neuroscience particularly those registered for a degree and at the start of their career. The Association recognises that such individuals can have relatively modest incomes. BAP does not wish financial considerations to prevent an individual from having a full and active engagement with the Association. Consequently, BAP offers the categories of (i) Training Membership and (ii) Student Registration for the Summer Meeting. Both Training Membership and Student Registration are only available to those with a low income and normally registered for a degree. If you feel there are special issues in your case, please contact the BAP Office for advice.Training Membership is limited to a maximum 5-year term or until the Member is employed in a full-time position, whichever is earliest.

Benefits of BAP membership include:• FREE subscription and online access to the Journal of Psychopharmacology• Reduced registration fees for the annual Summer Meeting• Half price subscription to the Online CPD Resource• Eligibility for prizes and awards• Student bursaries for the BAP Summer Meeting • Reduced registration fees for selected partner association events• BAP Newsletter• Voting for BAP Officers and Council Full and Early Career members only• Being part of one of the largest national psychopharmacology associations in the world

www.bap.org.uk/membershipform

49Harrogate 2017

BAP COURSES IN CLINICAL PSYCHOPHARMACOLOGY

MasterclassesForthcoming modules (all held in London)

Day ASchizophrenia

Substance Misuse

Day BBipolar | Perinatal |

ADHD

Day CDepression | Anxiety |

Sleep

22nd November 2017 23rd November 2017 24th November 2017

25th April 2018 26th April 2018 27th April 2018

21st November 2018 22nd November 2018 23rd November 2018

For more information and to book go to www.bap.org.uk/masterclasses

Clinical CertificateForthcoming Modules

Drug Treatments in Affective Disorders

28th September 2017 – 29th September 2017

Newcastle

Substance Misuse 7th December 2017 – 8th December 2017

Manchester

Anxiety Disorders25th January 2018 – 26th January 2018

Bristol

Schizophrenia 3rd May 2018 – 4th May 2018

Manchester

Drug Treatments in Old Age Psychiatry October 2018 Newcastle

Child & Adolescent Psychopharmacology November 2018 Newcastle

For more information and to book or register interest go to www.bap.org.uk/certificate

50 Harrogate 2017

ONLINE CPD RESOURCEA high quality, up-to-date resource taught by top experts in their field

Reviews of recent psychopharmacology papers, regularly updated

PLUSMultiple Choice Questions, printable certificate

on completion and reading lists

Schizophrenia Substance Misuse Including

Comorbidity Bipolar Disorder

Perinatal Disorders ADHD Focussing On Adult

Depression Anxiety Disorders

SleepOld Age

Child and Adolescent General Psychopharmacology

For more information and to subscribe go to

www.bap.org.uk/onlinecpd

£120 per year

non-members

£60per year

members and those who have registered or attended recent

BAP meetings/courses

£45per year

multiple users (10+)

Also available on iPad

51Harrogate 2017

FUNDAMENTALS OF CLINICAL PSYCHOPHARMACOLOGY

Fourth EditionWinner of the 2016 BMA Medical Book Award in Psychiatry, Fundamentals of Clinical Psychopharmacology provides up-to-date, evidence-based and unbiased information about psychopharmacology. It spans the range of the discipline, from mode of action and side effects of drugs to meta-analyses of clinical trials. It is anchored to practice guidelines produced by the UK National Institute for Health and Care Excellence (NICE) and the British Association for Psychopharmacology (BAP). Care has been taken to provide an international perspective that makes it equally useful to practitioners in the US and other countries.“This book is a well-designed, well-written and well-edited reference book. As it will address the CPD needs of the senior practitioner, it may have more information than a trainee will initially require but the accessible style will allow a discriminating approach to using the text. It is a concise reference that achieves its stated aim of delivering an up-to-date review of the most current understanding of the state of psychopharmacology to meet the needs of the busy senior practitioner but also trainees.” — BMA Book Award Judges.To buy a discounted copy of the new edition of the BAP book, Fundamentals of Clinical Psychopharmacology published in August 2015, for £20 (RRP £29.99), please go to

www.bap.org.uk/fundamentals

or visit the BAP Education stand in Studio 1